// App-Quantinova.ai

4574 : Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.

Researchers

Presenter

  • John B. A. G. Haanen

Principal Investigators

  • James Larkin

  • Toni K. Choueiri

  • Laurence Albiges

  • Brian I. Rini

  • Michael B. Atkins

  • Manuela Schmidinger

  • Konstantin Penkov

  • Despina Thomaidou

  • Jing Wang

  • Mariangela Mariani

  • Alessandra Di Pietro

  • Robert J. Motzer

Medical Centers

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, MA

  • Department of Cancer Medicine, Gustave Roussy Cancer Campus, University of Paris Sud, Boston, MA

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • Medical University of Vienna, Vienna, Austria

  • Private Medical Institution “Euromedservice”, Saint-Petersburg, Russian Federation

  • Pfizer Hellas, Athens, Greece

  • Pfizer Inc., Cambridge, MA

  • Pfizer Inc, Milan, Italy

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • Netherlands

  • United Kingdom

  • United States

  • Austria

  • Russia

  • Greece

  • Italy

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Sunitinib

  • Inlyta

  • Avelumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02684006

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved